Severe Combined Immunodeficiency Precision Panel

Overview

• Severe Combined Immunodeficiency (SCID) is a genetically heterogeneous group of disorders resulting from genetic defects in both cellular and humoral immunity where there is an impaired lymphocyte development and function. Aside from lymphocytes, other components of the innate and adaptive immune system such as neutrophils, macrophages, dendritic cells, complement proteins and natural killer cells are affected. Children present with bacterial, viral and fungal infections that begin during infancy and result in fatal outcome in the first few years of life if untreated. Early, accurate and precise diagnosis have enabled major advances in the care of infants with SCID, including better outcomes of allogeneic hematopoietic stem cell transplantation. The mode of inheritance of SCID determines the severity of the disease as different modes of inheritance will determine the immune cells that will be affected. Autosomal, sporadic or X-linked patterns may affect the neonate.  
• The Igenomix Severe Combined Immunodeficiency Precision Panel can be used for an accurate and directed diagnosis as well as differential diagnosis of early recurrent infections ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. 

Indication

• The Igenomix Severe Combined Immunodeficiency Precision Panel is used for patients with a clinical diagnosis or suspicion with or without the following symptoms: 
  • Neonate with a family history of a known immunologic disorder 
  • Failure to thrive 
  • Recurrent upper and lower respiratory tract infections that do not respond to antibiotics 
  • Recurrent skin infections and delayed wound healing 
  • Underdeveloped lymphoid tissue

Clinical Utility

The clinical utility of this panel is: 

• The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. 
• Early initiation of treatment involving a multidisciplinary team focusing on haematopoietic stem cell transplantation, IVIG infusions and other prophylactic antibiotics, gene therapy and enzyme replacement.  
• Risk assessment of asymptomatic family members according to the mode of inheritance via genetic counselling. 
• Improvement of delineation of genotype-phenotype correlation.  

Genes & Diseases